Title
Category
Credits
Event date
Cost
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
09/14/2021
$0.00
This Grand Rounds series is targeted to physician specialists in nephrology, cardiology, emergency medicine, and primary care, as well as pharmacists, nurses, nurse practitioners, and physician assistants who manage patients with ESRD.Supported through an independent educational grant from AstraZeneca.
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
09/16/2021
$0.00
This Grand Rounds series is targeted to physician specialists in nephrology, cardiology, emergency medicine, and primary care, as well as pharmacists, nurses, nurse practitioners, and physician assistants who manage patients with ESRD.Supported through an independent educational grant from AstraZeneca.
  • Oncology
  • ANCC
  • Participation
09/22/2021
$0.00
Nurse and physician expert faculty will discuss the emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.
  • Oncology
09/23/2021
$0.00
The Neurofibromatosis Young Investigators’ Forum (NFYIF) is a highly competitive research and professional development forum which strives to encourage, promote, and empower Young Investigators to forge collegial connections and acquire the necessary skills and relationships to increase their research productivity and catalyze their career trajectory in neurofibromatosis. The 2021 Forum will be our inaugural installment, and though we continue to closely monitor the ever-evolving conditions related to the COVID-19 pandemic, we are planning to provision a live, in-person format.
  • Oncology
  • ACPE Pharmacy
  • Participation
09/23/2021
$0.00
Attendees of this initiative will gain exposure to emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
09/25/2021
$0.00
Attendees of these regional meetings will gain an appreciation of the genes involved in the DNA damage response pathways and their role in tumorigenesis, the latest guidelines on genetic testing/counseling for mutations in this pathway, and the clinical implications of testing results (such as the use of PARP inhibitor for treatment). There will also be extensive discussion about the evolving role of the OB/GYN practitioner in genetic testing/counseling and management of ovarian cancer survivors on PARP inhibitor therapy.Presented by Creative Educational Concepts, Inc.
  • Oncology
  • ANCC
  • Participation
09/30/2021
$0.00
Nurse and physician expert faculty will discuss the emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.
  • AMA PRA Category 1 Credit™
  • Participation
10/04/2021
$0.00
This educational activity is targeted to pediatric neurologists, neuro-oncologists, neurosurgeons, and other members of the multidisciplinary NF1 care team attending the 2021 Child Neurology Society (CNS) Annual Meeting.
  • Oncology
  • ANCC
  • Participation
10/06/2021
$0.00
Nurse and physician expert faculty will discuss the emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.

Pages